Literature DB >> 35468725

GLUT4 gene rs5418 polymorphism is associated with increased coronary heart disease risk in a Uygur Chinese population.

Fei Yu1,2, Fen Liu1,2, Xiao-Mei Li2, Qian Zhao1,2, Jun-Yi Luo1,2, Jin-Yu Zhang1,3, Yi-Ning Yang4,5.   

Abstract

BACKGROUND: To explore possible associations between glucose transporter 4 (GLUT4) genetic polymorphisms in the patients with coronary heart disease (CHD) in Han and Uygur Chinese populations in Xinjiang, China.
METHODS: Two GLUT4 polymorphisms (rs5418 and rs5435) were genotyped in 1262 Han (628 CHD patients and 634 healthy controls) and 896 Uyghur (397 CHD patients and 499 healthy controls) Chinese populations.
RESULTS: In the Han Chinese population, there were no significant differences in allelic or genotypic distribution of rs5418 and rs5435 between the CHD and control groups (all P > 0.05). However, in the Uygur population, there were significant differences in genotype and allele distributions for rs5418 between CHD and the control group (all P < 0.05). Binary Logistic regression analysis showed that carriers with the rs5418 A allele had a higher risk of CHD compared to carriers of the rs5418 G allele (OR = 1.33, 95% CI: 1.069-1.649, P = 0.01), after adjustment for gender, age, drinking and smoking behavior, hypertension and diabetes. Furthermore, haploid association analysis of the two SNP loci of the GLUT4 gene showed that the AC haplotype was associated with CHD in the Uygur population (P = 0.001598; OR = 1.36, 95% CI = 1.1228-1.6406).
CONCLUSIONS: rs5418 GLUT4 gene variants are associated with CHD in the Uygur Chinese population.
© 2022. The Author(s).

Entities:  

Keywords:  Coronary heart disease; Glucose transporter 4 gene; Single nucleotide polymorphism; Susceptibility gene

Mesh:

Substances:

Year:  2022        PMID: 35468725      PMCID: PMC9036804          DOI: 10.1186/s12872-022-02630-9

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.174


Background

Coronary heart disease (CHD), also known as ischemic heart disease, is caused by myocardial ischemia and hypoxia due to changes in coronary circulation and represents the greatest mortality risk globally of all diseases. Prior reports suggest that ischemic heart disease causes 12.9 million deaths, accounting for one quarter of all global deaths annually, and is the main cause of death [1]. Many factors have been implicated in the development of coronary heart disease including smoking [2], obesity [3], sex [4], metabolic syndrome severity [5], glycerophosphocholine [6], dysglycemia and diabetes [7, 8], and sleep apnea syndrome [9, 10]. In addition to these environmental factors, several gene variants have been linked to the development and progression of CHD [11-13]. Glucose transporters (GLUT) are necessary for glucose uptake in cells of nearly all species [14]. Of the 14 known human GLUT genes, GLUT 1, 2, 3, and 4 have been implicated in human disease. In particular GLUT4 has been the subject of significant study as it is the main glucose transporter found in muscles and adipocytes [14]. This 12-transmembrane, 509-amino acid protein contains a large cytoplasmic loop between transmembrane helices 6 and 7 that is normally sequestered intracellularly in the basal state [15]. The cellular localization of GLUT4 is regulated by insulin through a complex mechanism, the aberration of which contributes to obesity [14]. The GLUT4 gene (also known as the solute carrier family 2, member 4 (17p13.2; OMIM 138190) encodes the GLUT4 solute carrier [16]. Many studies across multiple ethnicities have suggested a relationship between GLUT4 polymorphisms and human disease including insulin resistance [17-19], type 2 diabetes, [20] and obstructive sleep apnea syndrome [21]. However, few studies have investigated the association between the GLUT4 gene and CHD [22]. Thus, we aimed to evaluate a possible relationship between GLUT4 gene polymorphisms and CHD risk in Han and Uygur populations in Xinjiang, China.

Methods

Subjects

In this case–control study, patients with coronary angiography were recruited from the cardiovascular department of the First Affiliated Hospital of Xinjiang Medical University. The inclusion criteria for CHD are as follows: (1) older than 18 years of age, (2) a diagnosis of CHD according to the World Health Organization (WHO) CHD diagnostic criteria set in 1979, and (3) single vessel stenosis of > 70%, or multiple vessel stenosis of > 50%. The controls consisted of a random sample of adult’s individuals above 18 years of age who were visiting the hospital for a routine checkup and had medical records. The inclusion criteria were being devoid from any type of cardiovascular diseases and having a normal coronary artery with no evidence of plaque or peripheral vascular disease as confirmed by angiography, medical profile, or previous medical history as documented in their medical records. Individuals were excluded if they had the following conditions: cancer, acute or chronic inflammatory disease, cardiomyopathy or heart valve disease, variant angina without fixed coronary stenosis, coronary artery dilatation, X syndrome, serious liver disease (ALT > 2X normal), serious kidney disease (blood CR > 2.5 mg/dl), blood disease and pregnancy.

Clinical data collection

Baseline characteristics of all patients, such as sex, age, and smoking status were collected and are summarized in Table 1. Height and body mass were measured by a unified standard method, and patients' previous medical history such as hypertension, diabetes, abnormal blood lipid metabolism, and medications were recorded and used to diagnose related diseases in accordance with relevant Chinese or international standards [23, 24]. Habitual activities such as smoking and alcohol consumption behavior were collected from questionnaire.
Table 1

Baseline characteristic of the Han population

CharacteristicCHD(n = 628)Controls(n = 634)P
Sex (M/F)448/180290/344 < 0.001
Age, mean ± SD58.91 ± 12.4155.877 ± 10.19 < 0.001
BMI, mean ± SD25.29 ± 3.2524.98 ± 3.250.249
Drinking
0408473 < 0.001
197161
21230
Smoking
0101455 < 0.001
1245178
260
32761
Hypertension
No3203640.024
Yes308270
DM
No463572 < 0.001
Yes16562

SD standard deviation, BMI body mass index; Among the smokers, 0 means never smoking, 1 means occasional smoking, smoking cigarettes more than 4 times a week, but less than 1 cigarette per day on average, 2 means regular smoking, smoking cigarettes more than 1 cigarette per day, continuous or accumulative for 6 months. 3 represents heavy smoking, smoking more than 2 cigarettes a day for more than 6 months. Zero for non-drinking, 1 for occasional drinking, consuming about 10 g of alcohol per serving, and 2 for regular drinking, exceeding about 10 g of alcohol

Baseline characteristic of the Han population SD standard deviation, BMI body mass index; Among the smokers, 0 means never smoking, 1 means occasional smoking, smoking cigarettes more than 4 times a week, but less than 1 cigarette per day on average, 2 means regular smoking, smoking cigarettes more than 1 cigarette per day, continuous or accumulative for 6 months. 3 represents heavy smoking, smoking more than 2 cigarettes a day for more than 6 months. Zero for non-drinking, 1 for occasional drinking, consuming about 10 g of alcohol per serving, and 2 for regular drinking, exceeding about 10 g of alcohol

Blood biochemical indexes and DNA extraction

Cubital venous blood was collected from subjects after fasting for > 12 h. Blood biochemical indexes were tested by the Medical Laboratory Center of the First Affiliated Hospital of Xinjiang Medical University using the Abbott C16000 biochemical immunity instrument (United States). The Whole Blood Genome Extraction Kit (Tiangen Biochemical Co., Ltd.) was used to extract DNA from whole blood samples. A Nanodrop ND-2000 Ultramicro Nucleic Acid Analyzer was used to detect the concentration and purity of DNA, which was then diluted to 20 ng/ul.

Genotyping

In this study, single nucleotide polymorphisms (SNPs) were typed using the TM Multiple SNP Typing Kit (Shanghai Genesky Biotechnology). The SNP allelic site was identified using a high specificity ligase reaction. Then, the ligated products of different lengths were obtained by introducing varied length non-specific sequences at the end of the ligase probe and using a ligase addition reaction. The ligated products were PCR amplified using universal primers labeled with fluorescence, as shown in Supplementary material, and the amplified products were separated by fluorescence capillary electrophoresis. Finally, the genotypes of each SNP locus were obtained by analyzing the electrophoretic patterns.

Data analyses

SPSS 20.0 software was used for statistical analysis. Student t-test is applied for the continuous variables, while Pearson chi-square test is for categorical variables. Wilcoxon Rank-Sum test was applied for body mass index (BMI). The software program SHEsis or chi-square test (http://analysis.bio-x.cn) was used to assess Hardy- Weinberg equilibrium (HWE). PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) software was used to analyze the allelic and genotypic association with disease [25]. Linkage disequilibrium (LD) plot was generated from Haploview version 4.2 (Broad Institute, Cambridge, MA, United States) [26]. Haplotype association analyses were performed with PLINK. Binary logistic regression, with the adjustment of covariates was applied to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). Three logistic regression models (additive, dominant, and recessive) were also used to analyze the SNPs. All tests were two-tailed, and the results were considered significant when P ≤ 0.05.

Results

Baseline characteristics

The clinical characteristics of study subjects in the Han and Uygur populations are shown in Tables 1 and 2, respectively. Significant differences between both populations were noted in regard to gender (P < 0.001), age (P < 0.001), drinking and smoking behavior (P < 0.001), hypertension (P < 0.001) and diabetes (P < 0.001). Accordingly, these variants were used as the covariates in the following binary logistic regression analysis. No statically significant difference in the BMI was found between CHD patients and controls.
Table 2

Baseline characteristic of the Uygur population

CharacteristicCHD(n = 397)Controls(n = 499)P
Sex (M/F)280/117244/255 < 0.001
Age, mean ± SD55.864 ± 9.0052.374 ± 9.29 < 0.001
BMI, mean ± SD27.39 ± 3.6527.26 ± 4.310.787
Drinking
0291409 < 0.001
19590
2110
Smoking
0190376 < 0.001
1178123
210
3280
Hypertension
No1942820.026
Yes203217
DM
No291432 < 0.001
Yes10667

SD standard deviation, BMI body mass index; Among the smokers, 0 means never smoking, 1 means occasional smoking, smoking cigarettes more than 4 times a week, but less than 1 cigarette per day on average, 2 means regular smoking, smoking cigarettes more than 1 cigarette per day, continuous or accumulative for 6 months. 3 represents heavy smoking, smoking more than 2 cigarettes a day for more than 6 months. Zero for non-drinking, 1 for occasional drinking, consuming about 10 g of alcohol per serving, and 2 for regular drinking, exceeding about 10 g of alcohol

Baseline characteristic of the Uygur population SD standard deviation, BMI body mass index; Among the smokers, 0 means never smoking, 1 means occasional smoking, smoking cigarettes more than 4 times a week, but less than 1 cigarette per day on average, 2 means regular smoking, smoking cigarettes more than 1 cigarette per day, continuous or accumulative for 6 months. 3 represents heavy smoking, smoking more than 2 cigarettes a day for more than 6 months. Zero for non-drinking, 1 for occasional drinking, consuming about 10 g of alcohol per serving, and 2 for regular drinking, exceeding about 10 g of alcohol

Hardy–Weinberg analysis of the investigated SNPs

The Hardy–Weinberg analysis showed no deviations from Hardy–Weinberg Equilibrium for rs5418 and rs5435 in either the Han or Uygur populations.

Allelic and genotypic association with CHD

In the Han population, neither rs5418 nor rs5435 variants showed any significant differences in allelic frequencies and genotypic distribution between the CHD and control groups (all P > 0.05). However, in the Uygur population, the allelic frequencies of A and G at the rs5418 locus were 46.22 and 53.78% in the CHD group, and 39.28 and 60.72% in the control group, respectively, representing a significant difference in allelic distribution (P = 0.003, 95% CI = 1.10–1.61). The risk of having CHD in patients with the A allele was 1.33 times greater than that of the controls. The frequencies of the T and C alleles at the rs5435 locus in the Uygur CHD group were 33.12 and 66.88%, respectively, compared to 37.37 and 62.63% in the control group, respectively, representing no significant difference in the distribution of the alleles and genotypes between the two groups at the rs5435 locus (P = 0.06, OR = 0.83, 95% CI = 0.68–1.01). We conducted further binary logistic regressions based on the additive, dominant and recessive model after controlling for the influence of gender, age, drinking and smoking behavior, hypertension and diabetes, which revealed a significant association between the rs5418 locus and the risk of CHD under all the genetic models. Compared with the G allele, the A allele increased the risk of coronary heart disease 1.33×. These data are summaries in Tables 3, 4 and 5.
Table 3

Allelic association analysis between two SNPs and CHD

PopulationSNPAlleleGroupχ2PS.EOR (95%CI)
CHD group (%)Control group (%)
Hanrs5418A488 (38.85)495 (39.04)0.010.920.080.99 (0.85–1.16)
G768 (61.15)773 (60.96)
rs5435T397 (31.61)406 (32.02)0.050.820.090.98 (0.83–1.16)
C859 (68.39)862 (67.98)
Uygurrs5418A367 (46.22)392 (39.28)8.730.0030.101.33 (1.10–1.61)
G427 (53.78)606 (60.72)
rs5435T263 (33.12)373 (37.37)3.490.060.100.83 (0.68–1.01)
C531 (66.88)625 (62.63)
Table 4

Genotypic association analysis between two SNPs and CHD

PopulationSNPGenotypeCHD group (%)Control group (%)OR(95%CI)(P)
Dominant modelAdditive modelRecessive model
Hanrs5418AA99 (15.76)97 (15.30)0.97 (0.77–1.21) (0.76)Ref1.04 (0.76–1.41) (0.82)
AG290 (46.18)301 (47.48)1.06 (0.77–1.46) (0.73)
GG239 (38.06)236 (37.22)1.01 (0.72–1.41) (0.96)
rs5435TT59 (9.39)63 (9.94)0.99 (0.79–1.23) (0.92)Ref0.94 (0.65–1.37) (0.75)
TC279 (44.43)280 (44.16)0.94 (0.64–1.39) (0.76)
CC290 (46.18)291 (45.90)0.94 (0.64–1.39) (0.76)
Uygurrs5418AA82 (20.66)67 (13.43)1.36 (1.02–1.81) (0.03)Ref1.68 (1.18–2.39) (0.004)
AG203 (51.13)258 (51.70)1.56 (1.07–2.26) (0.020)
GG112 (28.21)174 (34.87)1.90 (1.27–2.84) (0.0017)
rs5435TT43 (10.84)66 (13.23)0.78 (0.59–1.02) (0.06)Ref0.80 (0.53–1.20) (0.28)
TC177 (44.58)241 (48.30)0.89 (0.58–1.36) (0.59)
CC177 (44.58)192 (38.47)0.71 (0.46–1.09) (0.12)
Table 5

Logistic regression analysis of GLUT4 polymorphisms and risk of coronary heart disease in the Uygur population

SNPAlleleTestOR (95% CI)P
rs5418A–GAdditive model1.33 (1.07–1.65)0.010
Dominant model1.36 (0.99–1.87)0.053
Recessive model1.59 (1.07–2.36)0.022
rs5435T–CAdditive model0.83 (0.67–1.03)0.089
Dominant model0.74 (0.55–0.99)0.048
Recessive model0.89 (0.57–1.28)0.590

For rs5418, genotype AA, AG and GG is coded as 0, 1 and 2 in additive model; AA, AG is coded as 0 and GG is coded as 1 in dominant model; AA is coded as 0 and AG, GG is coded as 1 in recessive model. For rs5435, genotype TT, TC and CC is coded as 0, 1 and 2 in additive model; TT, TC is coded as 0 and CC is coded as 1 in dominant model; TT is coded as 0 and TC, CC is coded as 1 in recessive model

Allelic association analysis between two SNPs and CHD Genotypic association analysis between two SNPs and CHD Logistic regression analysis of GLUT4 polymorphisms and risk of coronary heart disease in the Uygur population For rs5418, genotype AA, AG and GG is coded as 0, 1 and 2 in additive model; AA, AG is coded as 0 and GG is coded as 1 in dominant model; AA is coded as 0 and AG, GG is coded as 1 in recessive model. For rs5435, genotype TT, TC and CC is coded as 0, 1 and 2 in additive model; TT, TC is coded as 0 and CC is coded as 1 in dominant model; TT is coded as 0 and TC, CC is coded as 1 in recessive model We explored the correlations between rs5418 and other risk factors. There are no association identified between rs5418 and most of the risk factors. In Uygur population, genotype of rs5418 was significantly correlated with smoking behavior (Additional file 1: Tables S1, S2).

Haplotypes associated with CHD

Additional file 2: Figure S1 was included to show the linkage disequilibrium for the two investigated SNPs. In the Han population, haploid frequency analysis of two GLUT4 SNP loci identified three haplotypes at the two loci, yet there was no significant difference in the distribution of these haplotypes in the Han population (P > 0.05). In the Uygur population, haploid frequency analysis of two GLUT4 SNP loci identified four haplotypes. In particular, AC haplotype distribution was significantly different between the CHD and control groups in the Uygur population (P < 0.05) and the risk of developing CHD increased 1.36 for the AC haplotype carriers (Table 6).
Table 6

Association of haplotypes with CHD

Haplotype(Han)CHD groupn = 628Control groupn = 634χ2POR (95% CI)SNPs
GT3904000.0970.760.98 (0.83–1.16)rs5418|rs5435
AC4814900.030.860.99 (0.84–1.16)rs5418|rs5435
GC3853770.250.621.04 (0.88–1.24)rs5418|rs5435
Association of haplotypes with CHD

Discussion

Previous studies have shown close relationships between the incidence of CHD and LAP (liver-enriched transcriptional activator protein), (IL)-1 (interleukin 1), IL-18 (interleukin 18), ANGPTL4 (Angiopoietin-like 4), and PIN1 (Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1) [27-31] but few studies have investigated the association between GLUT4 polymorphisms and CHD. We studied GLUT4 polymorphisms and potential associations with CHD in multiple ethnic groups within a Chines population and identified a specific GLUT4 gene polymorphism that is significantly associated with the risk of developing CHD in the Uygur Chinese population. GLUT4 is the primary glucose transporter in the human heart, which accounts for approximately 70% of all glucose transport [32]. In heart diseases like cardiac hypertrophy, heart failure, and myocardial ischemia different perturbations in expression of glucose transporters are observed, especially in GLUT1 and GLUT4, due to changes in heart glucose metabolism. GLUT4 is translocated to the cell surface in response to ischemia, insulin, and catecholamines, allowing it to increase glucose transport into cardiomyocytes. However, in the absence of stimulation, GLUT4 is trapped intracellularly [33]. Ischemia, as seen in CHD, results in increased myocardial glucose utilization derived from glycogen breakdown [34] and also leads to increased glucose transport activity [35]. The increase in glucose uptake is due to the transport of GLUT1 and GLUT4 from the intracellular ventricle to the sarcolemma. Many studies have reported GLUT4 gene polymorphisms in association with type 2 diabetes [20, 36–38], but there are few investigations of possible GLUT4 gene polymorphisms in CHD patients. Of the known GLUT4 polymorphisms, rs5418 is located in the gene promoter region [39]. One prior study in a south India population found that the GLUT4 gene was detected in normal glucose tolerance and type 2 diabetes, and found differences in the ACGT haplotype of rs5418 [20]. Another study found that the rs5418 locus is associated with HBA1c levels in Japanese males [40]. The rs5418 locus has also been linked with obesity despite a similar allelic and genotypic distribution in extremely obese children and adolescents compared to normal and underweight patients, suggesting that these alleles are not involved in weight regulation [41]. The rs5435 locus was reported associated with risk of CHD in Han population in Guangdong province [22]. However, no significant association with CHD in Han and Uygur population in our study in allice and genotype distribution. The reason might be low sample size decreased the statistical power, since a significant trend was identified in logistic model under dominant model. In this study, we found that the genotypic and allelic frequencies of rs5418 locus were not significantly different in either the CHD or the control group of a Han Chinese population. However, in the Uygur population, we found that the distribution frequencies of the three genotypes and alleles in the two groups were significantly different. Differences in findings between these populations are likely related to the races studied. As a multi-ethnic region, Xinjiang has 45 ethnic groups, in addition to the Han and Uygur populations. In addition to the different genetic backgrounds of these groups, there are a variety of cultural and lifestyle differences that may also play a contributing role. Our findings that the AA genotype and the A allele at the rs5418 site GLUT4 gene are associated with susceptibility to CHD in the Uygur Chinese population, it may be beneficial provide for future clinical diagnosis and treatment. This study was limited to only patients from two ethnic groups in Xinjiang, China. Future studies should include more ethnic groups from this area or study populations in other regions of China or worldwide. Further functional validation of increased susceptibility to CHD development is also needed to confirm a definitive role of rs5418 site mutations in the GLUT4 gene and elucidate the effects of these mutations on CHD pathogenesis or etiology.

Conclusions

GLUT4 gene polymorphisms at the rs5418 site were associated with CHD susceptibility in the Uygur, but not Han, Chinese population of Xinjiang, China. Additional file 1: Table S1. Baseline characteristic of the Han population according to the genotype of rs5418. Table S2. Baseline characteristic of the Uygur population according to the genotype of rs5418. Additional file 2: Figure S1. Haploview analysis for D' and r2 pairwise measures of LD between rs5418 and rs5435. D' values and confidence levels (LOD) are represented as black for D' = 1, LOD > 2; shades of pink for high D', LOD < 2; white for D' < 1, LOD < 2. r2 values are represented as black for r2 = 1, white for r2 = 0, with intermediate values for 0 < r2 < 1 indicated by shades of grey. The numbers within the squares represent the D' or r2 scores for pairwise LD.
  39 in total

1.  Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance.

Authors:  A Zisman; O D Peroni; E D Abel; M D Michael; F Mauvais-Jarvis; B B Lowell; J F Wojtaszewski; M F Hirshman; A Virkamaki; L J Goodyear; C R Kahn; B B Kahn
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans.

Authors:  Inna Belfer; Beata Buzas; Catherine Evans; Heather Hipp; Gabriel Phillips; Julie Taubman; Ilona Lorincz; Robert H Lipsky; Mary-Anne Enoch; Mitchell B Max; David Goldman
Journal:  Eur J Hum Genet       Date:  2005-03       Impact factor: 4.246

3.  Genetic contribution of polymorphism of the GLUT1 and GLUT4 genes to the susceptibility to type 2 (non-insulin-dependent) diabetes mellitus in different populations.

Authors:  A E Pontiroli; F Capra; F Veglia; M Ferrari; K S Xiang; G I Bell; M G Baroni; D J Galton; J U Weaver; G A Hitman; P G Kopelman; V Mohan; M Viswanathan
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

Review 4.  Glucose transporters in healthy heart and in cardiac disease.

Authors:  Leszek Szablewski
Journal:  Int J Cardiol       Date:  2016-12-21       Impact factor: 4.164

5.  Crystal structure of a bacterial homologue of glucose transporters GLUT1-4.

Authors:  Linfeng Sun; Xin Zeng; Chuangye Yan; Xiuyun Sun; Xinqi Gong; Yu Rao; Nieng Yan
Journal:  Nature       Date:  2012-10-18       Impact factor: 49.962

6.  Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.

Authors:  Ming Zhong; Hong-wei Tan; Hui-ping Gong; Shu-fang Wang; Yun Zhang; Wei Zhang
Journal:  Clin Endocrinol (Oxf)       Date:  2008-03-20       Impact factor: 3.478

7.  Interleukin-18 (rs187238) and glucose transporter 4 (rs5435) polymorphisms in Euro-Brazilians with type 1 diabetes.

Authors:  Y Al-Lahham; A K B Mendes; E M Souza; D Alberton; F G M Rego; G Valdameri; G Picheth
Journal:  Genet Mol Res       Date:  2017-09-21

8.  Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.

Authors:  Nathan O Stitziel; Kathleen E Stirrups; Nicholas G D Masca; Jeanette Erdmann; Paola G Ferrario; Inke R König; Peter E Weeke; Thomas R Webb; Paul L Auer; Ursula M Schick; Yingchang Lu; He Zhang; Marie-Pierre Dube; Anuj Goel; Martin Farrall; Gina M Peloso; Hong-Hee Won; Ron Do; Erik van Iperen; Stavroula Kanoni; Jochen Kruppa; Anubha Mahajan; Robert A Scott; Christina Willenberg; Peter S Braund; Julian C van Capelleveen; Alex S F Doney; Louise A Donnelly; Rosanna Asselta; Piera A Merlini; Stefano Duga; Nicola Marziliano; Josh C Denny; Christian M Shaffer; Nour Eddine El-Mokhtari; Andre Franke; Omri Gottesman; Stefanie Heilmann; Christian Hengstenberg; Per Hoffman; Oddgeir L Holmen; Kristian Hveem; Jan-Håkan Jansson; Karl-Heinz Jöckel; Thorsten Kessler; Jennifer Kriebel; Karl L Laugwitz; Eirini Marouli; Nicola Martinelli; Mark I McCarthy; Natalie R Van Zuydam; Christa Meisinger; Tõnu Esko; Evelin Mihailov; Stefan A Escher; Maris Alver; Susanne Moebus; Andrew D Morris; Martina Müller-Nurasyid; Majid Nikpay; Oliviero Olivieri; Louis-Philippe Lemieux Perreault; Alaa AlQarawi; Neil R Robertson; Karen O Akinsanya; Dermot F Reilly; Thomas F Vogt; Wu Yin; Folkert W Asselbergs; Charles Kooperberg; Rebecca D Jackson; Eli Stahl; Konstantin Strauch; Tibor V Varga; Melanie Waldenberger; Lingyao Zeng; Aldi T Kraja; Chunyu Liu; George B Ehret; Christopher Newton-Cheh; Daniel I Chasman; Rajiv Chowdhury; Marco Ferrario; Ian Ford; J Wouter Jukema; Frank Kee; Kari Kuulasmaa; Børge G Nordestgaard; Markus Perola; Danish Saleheen; Naveed Sattar; Praveen Surendran; David Tregouet; Robin Young; Joanna M M Howson; Adam S Butterworth; John Danesh; Diego Ardissino; Erwin P Bottinger; Raimund Erbel; Paul W Franks; Domenico Girelli; Alistair S Hall; G Kees Hovingh; Adnan Kastrati; Wolfgang Lieb; Thomas Meitinger; William E Kraus; Svati H Shah; Ruth McPherson; Marju Orho-Melander; Olle Melander; Andres Metspalu; Colin N A Palmer; Annette Peters; Daniel Rader; Muredach P Reilly; Ruth J F Loos; Alex P Reiner; Dan M Roden; Jean-Claude Tardif; John R Thompson; Nicholas J Wareham; Hugh Watkins; Cristen J Willer; Sekkar Kathiresan; Panos Deloukas; Nilesh J Samani; Heribert Schunkert
Journal:  N Engl J Med       Date:  2016-03-02       Impact factor: 91.245

9.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Rafael Lozano; Mohsen Naghavi; Kyle Foreman; Stephen Lim; Kenji Shibuya; Victor Aboyans; Jerry Abraham; Timothy Adair; Rakesh Aggarwal; Stephanie Y Ahn; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Suzanne Barker-Collo; David H Bartels; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Kavi Bhalla; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; Fiona Blyth; Ian Bolliger; Soufiane Boufous; Chiara Bucello; Michael Burch; Peter Burney; Jonathan Carapetis; Honglei Chen; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Diego De Leo; Louisa Degenhardt; Allyne Delossantos; Julie Denenberg; Don C Des Jarlais; Samath D Dharmaratne; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Patricia J Erwin; Patricia Espindola; Majid Ezzati; Valery Feigin; Abraham D Flaxman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Sherine E Gabriel; Emmanuela Gakidou; Flavio Gaspari; Richard F Gillum; Diego Gonzalez-Medina; Yara A Halasa; Diana Haring; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Bruno Hoen; Peter J Hotez; Damian Hoy; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Ganesan Karthikeyan; Nicholas Kassebaum; Andre Keren; Jon-Paul Khoo; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Michael Lipnick; Steven E Lipshultz; Summer Lockett Ohno; Jacqueline Mabweijano; Michael F MacIntyre; Leslie Mallinger; Lyn March; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; John McGrath; George A Mensah; Tony R Merriman; Catherine Michaud; Matthew Miller; Ted R Miller; Charles Mock; Ana Olga Mocumbi; Ali A Mokdad; Andrew Moran; Kim Mulholland; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Kiumarss Nasseri; Paul Norman; Martin O'Donnell; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; David Phillips; Kelsey Pierce; C Arden Pope; Esteban Porrini; Farshad Pourmalek; Murugesan Raju; Dharani Ranganathan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Frederick P Rivara; Thomas Roberts; Felipe Rodriguez De León; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Joshua A Salomon; Uchechukwu Sampson; Ella Sanman; David C Schwebel; Maria Segui-Gomez; Donald S Shepard; David Singh; Jessica Singleton; Karen Sliwa; Emma Smith; Andrew Steer; Jennifer A Taylor; Bernadette Thomas; Imad M Tleyjeh; Jeffrey A Towbin; Thomas Truelsen; Eduardo A Undurraga; N Venketasubramanian; Lakshmi Vijayakumar; Theo Vos; Gregory R Wagner; Mengru Wang; Wenzhi Wang; Kerrianne Watt; Martin A Weinstock; Robert Weintraub; James D Wilkinson; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Paul Yip; Azadeh Zabetian; Zhi-Jie Zheng; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

10.  A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.

Authors:  Majid Nikpay; Anuj Goel; Hong-Hee Won; Leanne M Hall; Christina Willenborg; Stavroula Kanoni; Danish Saleheen; Theodosios Kyriakou; Christopher P Nelson; Jemma C Hopewell; Thomas R Webb; Lingyao Zeng; Abbas Dehghan; Maris Alver; Sebastian M Armasu; Kirsi Auro; Andrew Bjonnes; Daniel I Chasman; Shufeng Chen; Ian Ford; Nora Franceschini; Christian Gieger; Christopher Grace; Stefan Gustafsson; Jie Huang; Shih-Jen Hwang; Yun Kyoung Kim; Marcus E Kleber; King Wai Lau; Xiangfeng Lu; Yingchang Lu; Leo-Pekka Lyytikäinen; Evelin Mihailov; Alanna C Morrison; Natalia Pervjakova; Liming Qu; Lynda M Rose; Elias Salfati; Richa Saxena; Markus Scholz; Albert V Smith; Emmi Tikkanen; Andre Uitterlinden; Xueli Yang; Weihua Zhang; Wei Zhao; Mariza de Andrade; Paul S de Vries; Natalie R van Zuydam; Sonia S Anand; Lars Bertram; Frank Beutner; George Dedoussis; Philippe Frossard; Dominique Gauguier; Alison H Goodall; Omri Gottesman; Marc Haber; Bok-Ghee Han; Jianfeng Huang; Shapour Jalilzadeh; Thorsten Kessler; Inke R König; Lars Lannfelt; Wolfgang Lieb; Lars Lind; Cecilia M Lindgren; Marja-Liisa Lokki; Patrik K Magnusson; Nadeem H Mallick; Narinder Mehra; Thomas Meitinger; Fazal-Ur-Rehman Memon; Andrew P Morris; Markku S Nieminen; Nancy L Pedersen; Annette Peters; Loukianos S Rallidis; Asif Rasheed; Maria Samuel; Svati H Shah; Juha Sinisalo; Kathleen E Stirrups; Stella Trompet; Laiyuan Wang; Khan S Zaman; Diego Ardissino; Eric Boerwinkle; Ingrid B Borecki; Erwin P Bottinger; Julie E Buring; John C Chambers; Rory Collins; L Adrienne Cupples; John Danesh; Ilja Demuth; Roberto Elosua; Stephen E Epstein; Tõnu Esko; Mary F Feitosa; Oscar H Franco; Maria Grazia Franzosi; Christopher B Granger; Dongfeng Gu; Vilmundur Gudnason; Alistair S Hall; Anders Hamsten; Tamara B Harris; Stanley L Hazen; Christian Hengstenberg; Albert Hofman; Erik Ingelsson; Carlos Iribarren; J Wouter Jukema; Pekka J Karhunen; Bong-Jo Kim; Jaspal S Kooner; Iftikhar J Kullo; Terho Lehtimäki; Ruth J F Loos; Olle Melander; Andres Metspalu; Winfried März; Colin N Palmer; Markus Perola; Thomas Quertermous; Daniel J Rader; Paul M Ridker; Samuli Ripatti; Robert Roberts; Veikko Salomaa; Dharambir K Sanghera; Stephen M Schwartz; Udo Seedorf; Alexandre F Stewart; David J Stott; Joachim Thiery; Pierre A Zalloua; Christopher J O'Donnell; Muredach P Reilly; Themistocles L Assimes; John R Thompson; Jeanette Erdmann; Robert Clarke; Hugh Watkins; Sekar Kathiresan; Ruth McPherson; Panos Deloukas; Heribert Schunkert; Nilesh J Samani; Martin Farrall
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.